Candace T. Westgate, DO, MPH, FACOG
Medical Director
AHEAD Hereditary Cancer Risk Assessment Programs
Adventist Health – St. Helena Women's Center
St. Helena, California
Ethan D. Schram, MD, FACP
Medical Director, Oncology
Adventist Health – Martin-O’Neil Cancer Center
St. Helena, California

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and physician assistants specializing in primary care, obstetrics and gynecology, geriatrics, and other relevant specialties.

Program Overview

Early detection of cancer is essential to reducing the significant burdens associated with it. When cancer is detected at earlier stages, treatments can be initiated sooner, resulting in improved outcomes, reduced morbidity and mortality, and better quality of life. While the implementation of current screening guidelines has resulted in an overall reduction in cancer deaths, only 25% of cancers are diagnosed using traditional screening modalities, leaving much room for improvement. Blood-based multi-cancer early detection (MCED) tests that can screen from 4 to >50 types of cancers have been developed to complement the population-based screening of asymptomatic individuals. At the spring 2023 American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and National Comprehensive Cancer Network (NCCN) annual conferences, a multitude of data was presented on MCEDs, including real-world data, clinical trial data, novel MCEDs in development, MCED accuracy, and the inherent health equity challenges that their implementation will face. This educational activity has 2 parts: Dr. Candace Westgate delivers an MCED Primer designed to build primary care clinicians’ knowledge about the science of MCEDs and how to implement their use in primary care practice, followed by chapterized discussions between Dr. Westgate and Dr. Ethan Schram on the various MCED-related data presented at the AACR, ASCO, and NCCN 2023 oncology conferences.

Educational Objectives

After completing this activity, the participant should be better able to:

  1. Identify gaps in current cancer screening and the potential role of blood-based tests to improve early cancer detection
  2. Explain the scientific basis of blood-based multi-cancer early detection tests
  3. Describe the most recent clinical trial data on available and investigational noninvasive multi-cancer screening tests emerging from national oncology conference presentations
  4. Integrate MCED and patient counseling into primary care settings

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For information about the accreditation (ACCME credit) of this program, please contact Integritas at info@exchangecme.com.

Global Contact Information

For information about the accreditation (ANCC credit) of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 75% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Relevant Financial Relationships

Integritas and Global Education Group (Global) adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas and Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas and Global.  All financial relationships reported are identified as relevant and mitigated by Integritas and Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas and Global to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Candace T. Westgate, DO, MPH, FACOG: Consulting Fee: Myriad Genetics, Inc.; Speakers Bureau: GRAIL, Myriad Genetics, Inc.

Ethan D. Schram, MD, FACP: Nothing to disclose

The planners and managers at Integritas Communications and Global Education Group have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications and Global Education Group (Global) do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Begin Activity
available resources
linked resources
Suggested Reading
A Hot Topics Podcast

Hot Topics in Blood-based Cancer Screening

Key Information on Multi-Cancer Early Detection from 2023 Spring Oncology Meetings